Drug Repositioning Bringing New Life To Shelved Assets And Existing Drugs Michael J Barratt by Michael J. Barratt, Donald E. Frail 9780470878279, 9781118274408, 0470878274, 1118274407 instant download after payment.

The how's and why's of successful drug repositioning

Drug repositioning, also known as drug reprofiling or repurposing, has become an increasingly important part of the drug development process. This book examines the business, technical, scientific, and operational challenges and opportunities that drug repositioning offers. Readers will learn how to perform the latest experimental and computational methods that support drug repositioning, and detailed case studies throughout the book demonstrate how these methods fit within the context of a comprehensive drug repositioning strategy.

Drug Repositioning is divided into three parts:

• Part 1, Drug Repositioning: Business Case, Strategies, and Operational Considerations, examines the medical and commercial drivers underpinning the quest to reposition existing drugs, guiding readers through the key strategic, technical, operational, and regulatory decisions needed for successful drug repositioning programs.

• Part 2, Application of Technology Platforms to Uncover New Indications and Repurpose Existing Drugs, sets forth computational-based strategies, tools, and databases that have been designed for repositioning studies, screening approaches, including combinations of existing drugs, and a look at the development of chemically modified analogs of approved agents.

• Part 3, Academic and Non-Profit Initiatives & the Role of Alliances in the Drug Repositioning Industry, explores current investigations for repositioning drugs to treat rare and neglected diseases, which are frequently overlooked by for-profit pharmaceutical companies due to their lack of commercial return.

The book's appendix provides valuable resources for drug repositioning researchers, including information on drug repositioning and reformulation companies, databases, government resources and organizations, regulatory agencies, and drug repositioning initiatives from academia and non-profits.

With this book as their guide, students and pharmaceutical researchers can learn how to use drug repositioning techniques to extend the lifespan and applications of existing drugs as well as maximize the return on investment in drug research and development.

Content:
Chapter 1 Drug Repositioning: The Business Case and Current Strategies to Repurpose Shelved Candidates and Marketed Drugs (pages 7–32): John Arrowsmith and Richard Harrison
Chapter 2 Opportunities and Challenges Associated with Developing Additional Indications for Clinical Development Candidates and Marketed Drugs (pages 33–51): Donald E. Frail and Michael J. Barratt
Chapter 3 Clinical and Operational Considerations in Repositioning Marketed Drugs and Drug Candidates (pages 53–64): Damian O'connell, David J. Sequeira and Maria L. Miller
Chapter 4 Regulatory Considerations and Strategies for Drug Repositioning (pages 65–88): Ken Phelps
Chapter 5 Computational and Bioinformatic Strategies for Drug Repositioning (pages 89–135): Richard Mazzarella and Craig Webb
Chapter 6 Mining Scientific and Clinical Databases to Identify Novel Uses for Existing Drugs (pages 137–161): Christos Andronis, Anuj Sharma, Spyros Deftereos, Vassilis Virvilis, Ourania Konstanti, Andreas Persidis and Aris Persidis
Chapter 7 Predicting the Polypharmacology of Drugs: Identifying New Uses through Chemoinformatics, Structural Informatics, and Molecular Modeling?Based Approaches (pages 163–205): Li Xie, Sarah L. Kinnings, Lei Xie and Philip E. Bourne
Chapter 8 Systematic Phenotypic Screening for Novel Synergistic Combinations: A New Paradigm for Repositioning Existing Drugs (pages 207–252): Margaret S. Lee
Chapter 9 Phenotypic In Vivo Screening to Identify New, Unpredicted Indications for Existing Drugs and Drug Candidates (pages 253–290): Michael S. Saporito, Christopher A. Lipinski and Andrew G. Reaume
Chapter 10 Old Drugs Yield New Discoveries: Examples from the Prodrug, Chiral Switch, and Site?Selective Deuteration Strategies (pages 291–343): Adam J. Morgan, Bhaumik A. Pandya, Craig E. Masse and Scott L. Harbeson
Chapter 11 Repurposing Drugs for Tropical Diseases: Case Studies and Open?Source Screening Initiatives (pages 345–388): Curtis R. Chong
Chapter 12 Drug Repositioning Efforts by Nonprofit Foundations (pages 389–431): Donald E. Frail, Louis Degennaro, Aaron Schimmer, James Kasper, Richard Winneker, Todd B. Sherer, Alison Urkowitz, Kuldip D. Dave, Jill Panetta and John McCall
Chapter 13 Business Development Strategies in the Repositioning Industry (pages 433–444): Aris Persidis and Elizabeth T. Stark
Chapter 14 A Case Study in Drug Repositioning: Sosei (pages 445–456): Akinori Mochizuki and Makiko Aoyama